公开(公告)号：US20240002368A1

公开(公告)日：2024-01-04

申请号：US18037965

申请日：2021-11-23

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Hailong Li ,  Wenge Zhong ,  Wei Huang

IPC: C07D403/12 ,  C07D471/04 ,  C07D405/14 ,  C07D403/14 ,  C07D413/14

CPC classification number: C07D403/12 ,  C07D471/04 ,  C07D405/14 ,  C07D403/14 ,  C07D413/14

Abstract: The present disclosure provides compounds of Formula (I) a pharmaceutically acceptable salt, a stereoisomer, or a tautomer thereof, for use in, e.g. treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

公开(公告)号：US20220389037A1

公开(公告)日：2022-12-08

申请号：US17624514

申请日：2020-07-03

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Xiaotian Zhu ,  Song Feng ,  Lei Wu ,  Wei Huang ,  Hao Liu ,  Rongqiang Liu ,  Kate Xin Wen ,  Hua Zhou

IPC: C07F9/6561 ,  C07D401/14 ,  C07D405/14 ,  C07D471/04 ,  C07D519/00 ,  C07D491/107 ,  C07D487/04 ,  C07D473/32 ,  C07F9/6558 ,  C07D498/04 ,  A61K45/06

Abstract: Provided herein is a compound represented by structural formula (I-0) or formula (II): or a pharmaceutically acceptable salt or a stereoisomer thereof useful for treating diseases (such as cancer) that are treatable by inhibiting HPK1 activity.

公开(公告)号：US20240051956A1

公开(公告)日：2024-02-15

申请号：US18268914

申请日：2021-12-21

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Kailiang Wang ,  Zhilong Hu ,  Fei Zhang ,  Wei Huang ,  Teng Feng ,  Fei Xiao ,  Wenge Zhong

IPC: C07D471/04 ,  C07D519/00 ,  A61P35/00

CPC classification number: C07D471/04 ,  C07D519/00 ,  A61P35/00

Abstract: The present disclosure provides a compound of Formula (I) a pharmaceutically acceptable salt or a stereoisomer and their use in, e.g. treating a condition, disease or disorder in which the inhibition of the interaction of SOS 1 and a RAS-family protein or RAC1 is of therapeutic benefit, specifically in treating oncological diseases. This disclosure also features compositions containing the same as well as methods of using and making the same.

公开(公告)号：US20230339896A1

公开(公告)日：2023-10-26

申请号：US18013402

申请日：2021-07-02

Applicant: QILU REGOR THERAPEUTICS INC.

Inventor： Wenge Zhong ,  Xiaotian Zhu ,  Song Feng ,  Lei Wu ,  Wei Huang ,  Hao Liu ,  Rongqiang Liu ,  Kate Xin Wen ,  Hua Zhou

IPC: A61P35/00 ,  C07D401/14

CPC classification number: C07D401/14 ,  A61P35/00

Abstract: The invention provides a compound represented by structural formula (I) or formula (II), or a pharmaceutically acceptable salt or a stereoisomer thereof useful for treating diseases (such as cancer) that are treatable by inhibiting HPKl activity.